Myeloid Differentiation Factor 88
"Myeloid Differentiation Factor 88" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An intracellular signaling adaptor protein that plays a role in TOLL-LIKE RECEPTOR and INTERLEUKIN 1 RECEPTORS signal transduction. It forms a signaling complex with the activated cell surface receptors and members of the IRAK KINASES.
| Descriptor ID |
D053594
|
| MeSH Number(s) |
D12.644.360.024.311 D12.776.157.057.074 D12.776.476.024.390
|
| Concept/Terms |
Myeloid Differentiation Factor 88- Myeloid Differentiation Factor 88
- Toll-Like Receptor Signal Adaptor Protein MyD88
- Toll Like Receptor Signal Adaptor Protein MyD88
- MyD88 Protein
- TLR Signal Adaptor Protein MyD88
|
Below are MeSH descriptors whose meaning is more general than "Myeloid Differentiation Factor 88".
Below are MeSH descriptors whose meaning is more specific than "Myeloid Differentiation Factor 88".
This graph shows the total number of publications written about "Myeloid Differentiation Factor 88" by people in this website by year, and whether "Myeloid Differentiation Factor 88" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 6 | 3 | 9 |
| 2017 | 3 | 3 | 6 |
| 2018 | 5 | 5 | 10 |
| 2019 | 1 | 5 | 6 |
| 2020 | 5 | 4 | 9 |
| 2021 | 6 | 3 | 9 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 2 | 2 |
| 2025 | 3 | 0 | 3 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloid Differentiation Factor 88" by people in Profiles.
-
POD24 is a novel determinant of prognosis in patients with Waldenstr?m macroglobulinemia. Blood Adv. 2026 Apr 14; 10(7):2322-2327.
-
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. J Med Chem. 2026 Jan 22; 69(2):1119-1134.
-
Dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation. J Virol. 2025 05 20; 99(5):e0065325.
-
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenstr?m macroglobulinaemia. Br J Haematol. 2025 Jun; 206(6):1604-1614.
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
-
Health-related quality of life in patients with Waldenstr?m macroglobulinemia: results from the ASPEN trial. Future Oncol. 2024; 20(25):1789-1798.
-
How I use genomics and BTK inhibitors in the treatment of Waldenstr?m macroglobulinemia. Blood. 2024 04 25; 143(17):1702-1712.
-
Therapeutic effect of Echinococcus granulosus cyst fluid on bacterial sepsis in mice. Parasit Vectors. 2023 Dec 08; 16(1):450.
-
Toll-like receptor 2 selectively modulates Ras isoforms expression in Leishmania major infection. Cytokine. 2023 09; 169:156301.
-
Evaluation and Management of Disease Transformation in Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2023 08; 37(4):787-799.